Netherlands· NL-403c6b042575
Ranluspec 10 mg/ml oplossing voor injectie in een voorgevulde spuit
A ranibizumab product containing ranibizumab, registered in Netherlands by Lupin Europe GmbH. The same ATC class is registered in 15 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Ranibizumab is registered in 15 of 19 countries.
Countries holding a registration under ATC S01LA04 (ranibizumab), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 9 of them publish a price we can compare per daily dose
Ranibizumab · ATC S01LA04
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- RANIBIZUMAB
- Manufacturer
- Lupin Europe GmbH
- Country
- Netherlands (NL)
- ATC code
- S01LA04
- ATC class
- Ranibizumab
- Defined daily dose
- 0.036 DE, IVT
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/25/2012
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ranibizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaBYOOVIZSamsung Bioepis NL B.V., Delft
- SwedenByooviz 10 mg/ml Injektionsvätska, lösningSamsung Bioepis NL B.V.
- BelgiumByooviz 10 mg/mlSamsung Bioepis NL
- SpainBYOOVIZ 10 MG/ML SOLUCION INYECTABLESamsung Bioepis Nl B.V.
- PolandByoovizSamsung Bioepis NL B.V.
- IcelandByoovizSamsung Bioepis NL B.V.
- SwitzerlandByooviz
- IrelandByooviz 10 mg/ml solution for injectionSamsung Bioepis NL B.V.
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Ximluci
- Iceland · Epruvy, Lucentis
- Liechtenstein · Epruvy, Lucentis
- Norway · Epruvy, Lucentis
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ada2cd3d-d0e9-4e79-a0c8-c4c6610a82f4 GET /v1/drugs/ada2cd3d-d0e9-4e79-a0c8-c4c6610a82f4?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Oplossing voor injectie",
"route": "Intravitreaal gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/ranluspec-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Ranibizumab",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp134698",
"excipients": [
"HISTIDINE, (L-)",
"HISTIDINEMONOHYDROCHLORIDE 1-WATER (L-)",
"POLYSORBAAT 20 (E 432)",
"TREHALOSE (Alpha, Alpha-) 2-WATER",
"WATER VOOR INJECTIE"
],
"substances": [
"RANIBIZUMAB"
],
"leaflet_url": null,
"authorised_at": "2026/02/10",
"procedure_number": "EMEA/H/C/006502",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/25/2012",
"additional_monitoring": "Y"
}See everything about ranibizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.